Search results for "platelet aggregation inhibitors"

showing 10 items of 105 documents

Microvascular in vivo assessment of reperfusion injury: significance of prostaglandin E1 and I2 in postischemic “no-reflow” and “reflow-paradox”

2004

Microvascular ischemia-reperfusion (I/R) injury is characterized by failure of capillary perfusion ("no-reflow") and reoxygenation-associated phenomena ("reflow-paradox"), including activation of leukocyte-endothelium interaction with cytotoxic mediator-induced loss of endothelial integrity. The objectives of this study were to elucidate the impact of both prostaglandins E(1) (PGE(1)) and I(2) (PGI(2)) in microvascular reperfusion injury, with special focus on the distinct pathophysiology of no-reflow- and reflow-paradox phenomena.By use of the hamster dorsal skinfold preparation and in vivo fluorescence microscopy, the microcirculation of a striated skin muscle was assessed before 4 h of p…

Pathologymedicine.medical_specialtyEndotheliummedicine.medical_treatmentIschemiaPharmacologyMicrocirculationCapillary Permeabilitychemistry.chemical_compoundIn vivoCricetinaemedicineAnimalsVascular Diseasescardiovascular diseasesAlprostadilMuscle SkeletalProstaglandin E1SkinMicroscopyMesocricetusbusiness.industryMicrocirculationmedicine.diseaseEpoprostenolPathophysiologyCapillariesChemotaxis Leukocytemedicine.anatomical_structurechemistryReperfusion InjuryModels Animalcardiovascular systemSurgeryEndothelium VascularbusinessReperfusion injuryPlatelet Aggregation InhibitorsProstaglandin EJournal of Surgical Research
researchProduct

C-reactive protein and efficacy of antiplatelet therapy in (intracranial) atherosclerosis

2018

C-reactive protein (CRP) and other inflammatory biomarkers can indicate both the severity and extent of atherosclerosis, reflecting the inflammatory nature of the disease process.1 Atherogenesis begins with an inflammatory response to vascular injury with cells and mediators initiating the healing response and later inducing growth of atherosclerotic plaques. Inflammation then increases plaque instability, promoting rupture, fissuring, or erosion—the pathogenetic milieu of thrombosis in atherothrombotic ischemic strokes.

Pathologymedicine.medical_specialtyInflammationConstriction PathologicDisease030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemedicineHumansbiologyC-reactive protein intracranial atherosclerosisbusiness.industryIschemic strokesC-reactive proteinAtherosclerosismedicine.diseaseThrombosisInflammatory biomarkersC-Reactive Proteinbiology.proteinPlatelet aggregation inhibitorNeurology (clinical)Intracranial Atherosclerosismedicine.symptombusinessPlatelet Aggregation Inhibitors030217 neurology & neurosurgeryNeurology
researchProduct

Consensus document on intermittent claudication from the Central European Vascular Forum 1st edition - Abano Terme (Italy) - May 2005 2nd revision - …

2008

Peripheral Vascular DiseasesLegtrainingTiclopidineAspirinAcetylsalicylic acidanticoagulant agentantithrombocytic agentconsensus document; intermittent claudicatio; training; antiplatelets' therapyintermittent claudicatioIntermittent ClaudicationSettore MED/11 - Malattie Dell'Apparato CardiovascolareClopidogrelantiplatelets' therapyIschemiaDisease ProgressionExercise TestHumansCarotid StenosisUltrasonography Doppler Colorconsensus documentPlatelet Aggregation Inhibitors
researchProduct

Occurrence of resveratrol and pterostilbene in age-old darakchasava, an ayurvedic medicine from India

2000

'Darakchasava' is a well known Indian herbal preparation of which the main ingredient is Vitis vinifera L. This 'ayurvedic' medicine is prescribed as a cardiotonic and also given for other disorders. HPLC analysis of this age old formulation revealed the presence of polyphenols like resveratrol and pterostilbene. These phenolic compounds are now known as antioxidants, cancer chemopreventive agents, and also known to reduce mortality from coronary heart disease by increasing high density lipoproteins like cholesterol and inhibiting platelet aggregation (Soleas, J.S., Diamandis, E.P., Goldberg, D.M., 1997. Resveratrol: a molecule whose time has come? and gone? Clin. Biochem. 30 (2), 91-113). …

PharmacologyPterostilbeneTraditional medicinePlant ExtractsCholesterolIndiafood and beveragesPharmacognosyResveratrolAntineoplastic Agents PhytogenicAntioxidantsMedicine Ayurvedicchemistry.chemical_compoundIngredientPhenolschemistryResveratrolPolyphenolStilbenesDrug DiscoveryHypoglycemic AgentsPlatelet aggregation inhibitorVitis viniferaChromatography High Pressure LiquidPlatelet Aggregation InhibitorsJournal of Ethnopharmacology
researchProduct

Editorial: Ischemic Stroke Prevention

2014

Pharmacologymedicine.medical_specialtySettore MED/09 - Medicina Internabusiness.industryStroke ischemic PreventionBrain IschemiaStrokeInternal medicineIschemic strokemedicineCardiologyAnimalsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsCurrent Vascular Pharmacology
researchProduct

Platelet function testing in pigs using the Multiplate® Analyzer.

2019

PLOS ONE 14(8), e0222010 (2019). doi:10.1371/journal.pone.0222010

Platelet AggregationSwinePhysiology030204 cardiovascular system & hematologyPlatelet inhibitionPharmacologyAntiplatelet Therapy0302 clinical medicineOral administrationAnimal CellsPig ModelsMedicine and Health SciencesMedicinePlateletOral AdministrationRoutes of AdministrationMammalsMultidisciplinaryPharmaceuticsQREukaryotaHematologyAnimal ModelsClopidogrelBody FluidsBloodExperimental Organism SystemsVertebratesMedicineAnatomyCellular Typesmedicine.drugResearch ArticleBlood PlateletsPlateletsPlatelet Function TestsScience610Research and Analysis Methods03 medical and health sciencesAnimal modelDrug TherapyAnimalsddc:610Platelet activationBlood CoagulationApplication methodsPharmacologyBlood CellsAspirinbusiness.industryOrganismsBiology and Life Sciences030208 emergency & critical care medicineCell BiologyPlatelet ActivationReference valuesAmniotesPurinergic P2Y Receptor AntagonistsAnimal StudiesbusinessPlatelet Aggregation InhibitorsPloS one
researchProduct

Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation

2013

Background Scores for cardio-embolic and bleeding risk in patients with atrial fibrillation are described in the literature. However, it is not clear how they co-classify elderly patients with multimorbidity, nor whether and how they affect the physician's decision on thromboprophylaxis. Methods Four scores for cardio-embolic and bleeding risks were retrospectively calculated for ≥ 65 year old patients with atrial fibrillation enrolled in the REPOSI registry. The co-classification of patients according to risk categories based on different score combinations was described and the relationship between risk categories tested. The association between the antithrombotic therapy received and t…

RegistrieMaleEmbolismAtrial fibrillation; Bleeding risk; Cardioembolic risk; Elderly; Prediction guides; Thromboprophylaxis; Aged; Aged; 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Female; Hemorrhage; Humans; Logistic Models; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Warfarin; Registries; Risk Assessment; Internal MedicineRetrospective Studiearitmiableeding risk scoreAtrial Fibrillation80 and overatrial fibrillationRegistriesStrokeAged 80 and overAspirineducation.field_of_studyElderly Atrial fibrillation Prediction guides Bleeding risk Cardioembolic risk ThromboprophylaxisPrediction guidesAtrial fibrillationCardiovascular diseaseStrokecardio-embolic scorePlatelet aggregation inhibitorcardio-embolic scores; bleeding risk scores; elderly; Atrial FibrillationFemaleRisk assessmentmedicine.drugHumanmedicine.medical_specialtyLogistic Modelcardio-embolic scoresPopulationHemorrhageRisk AssessmentelderlyCARDIOEMBOLIC RISKNOBLEEDING RISKInternal medicinemedicineElderly; Atrial fibrillation; Prediction guides; Bleeding risk; Cardioembolic riskbleeding risk scoresPrediction guideInternal MedicineHumanseducationThromboprophylaxisAgedRetrospective StudiesELDERLYbusiness.industryPlatelet Aggregation InhibitorSettore MED/09 - MEDICINA INTERNAWarfarinAnticoagulantAnticoagulantsRetrospective cohort studyAtrial fibrillation; Bleeding risk; Cardioembolic risk; Elderly; Prediction guides; Thromboprophylaxis; Aged; Aged 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Female; Hemorrhage; Humans; Logistic Models; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Warfarin; Registries; Risk Assessment; Internal Medicinemedicine.diseaseSurgeryLogistic ModelsThromboprophylaxiWarfarinbusinessPlatelet Aggregation Inhibitors
researchProduct

Mortality rate and risk factors for gastrointestinal bleeding in elderly patients

2019

Abstract Background Gastrointestinal bleeding (GIB) is burdened by high mortality rate that increases with aging. Elderly patients may be exposed to multiple risk factors for GIB. We aimed at defining the impact of GIB in elderly patients. Methods Since 2008, samples of elderly patients (age ≥ 65 years) with multimorbidity admitted to 101 internal medicine wards across Italy have been prospectively enrolled and followed-up (REPOSI registry). Diagnoses of GIB, length of stay (LOS), mortality rate, and possible risk factors, including drugs, index of comorbidity (Cumulative Illness Rating Scale [CIRS]), polypharmacy, and chronic diseases were assessed. Adjusted multivariate logistic regressio…

RegistrieMaleSettore MED/09 - Medicina Interna030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineRisk Factors80 and over030212 general & internal medicineHospital MortalityProspective StudiesRegistriesProspective cohort studyMultivariate AnalysiAged 80 and overDiverticulosisMortality rateDiverticulosiGastric ulcerAnemiaAnemia; Anticoagulant; Antiplatelet drug; Diverticulosis; Gastric ulcer; Multimorbidity; Internal MedicineItalyPlatelet aggregation inhibitorFemaleGastrointestinal HemorrhageAntiplatelet drugHumanGastrointestinal bleedingmedicine.medical_specialtyLogistic ModelAnemiaSocio-culturaleAnemia Anticoagulant Antiplatelet drug Diverticulosis Gastric ulcer Multimorbidity03 medical and health sciencesInternal medicineSeverity of illnessInternal MedicinemedicineHumansAnemia; Anticoagulant; Antiplatelet drug; Diverticulosis; Gastric ulcer; Multimorbidity; Aged; Aged 80 and over; Female; Gastrointestinal Hemorrhage; Hospital Mortality; Humans; Italy; Length of Stay; Logistic Models; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk Factors; Severity of Illness Index; MultimorbidityAgedPolypharmacybusiness.industryPlatelet Aggregation InhibitorRisk FactorAnemia; Anticoagulant; Antiplatelet drug; Diverticulosis; Gastric ulcer; MultimorbidityAnticoagulantMultimorbidityAnemia Anticoagulant Antiplatelet drug Diverticulosis Gastric ulcer Multimorbidity Aged Aged 80 and over Female Gastrointestinal Hemorrhage Hospital Mortality Humans Italy Length of Stay Logistic Models Male Multivariate Analysis Platelet Aggregation Inhibitors Prospective Studies Registries Risk Factors Severity of Illness Index MultimorbidityLength of Staymedicine.diseaseComorbidityProspective StudieLogistic ModelsMultivariate AnalysisbusinessPlatelet Aggregation Inhibitors
researchProduct

Current practice in managing patients on anticoagulants and/or antiplatelet agents around the time of gastrointestinal endoscopy -- a nation-wide sur…

2004

Anticoagulants and antiplatelet agents are widely used in the prophylaxis and management of thromboembolic and cardiovascular diseases. Gastrointestinal bleeding is a well-known complication of these agents. Modification of anticoagulant and antiplatelet therapy is often required in patients undergoing surgical procedures and specific recommendations for the perioperative period have been issued. Fewer data exist with regard to the use of these agents around the time of endoscopic procedures. A survey of the American Society for Gastrointestinal Endoscopy (ASGE), performed several years ago, showed a wide variation between endoscopists in the management of anticoagulants and antiplatelet ag…

Riskmedicine.medical_specialtyGastrointestinal bleedingmedicine.drug_classMEDLINEEndoscopy GastrointestinalGermanySurveys and QuestionnairesMedicineHumansIntensive care medicineBlood coagulation testmedicine.diagnostic_testbusiness.industryAnticoagulantGastroenterologyWarfarinAnticoagulantsPerioperativemedicine.diseaseSurgeryEndoscopyBlood Coagulation TestsGuideline AdherencebusinessComplicationGastrointestinal HemorrhagePlatelet Aggregation Inhibitorsmedicine.drugZeitschrift fur Gastroenterologie
researchProduct

Stroke subtypes and their possible implication in stroke prevention drug strategies

2014

Thrombotic strokes can affect large or small arteries in the brain. Drugs to prevent atherosclerosis complication such as thrombotic strokes, should be drugs able to prevent the accumulation of intravascular fat, reduce vascular proliferation, decrease blood pressure levels with the resulting shear stress, reduce platelet aggregation, and possibly partially or totally reverse carotid plaques. Any of the commonly used antihypertensive drugs lower the incidence of stroke, with larger reductions in BP resulting in larger reductions in risk. Experimental and clinical data suggest that reducing the activity of the renin-angiotensin aldosterone system (RAAS) may have beneficial effects beyond the…

TOAST ClassificationDrugmedicine.medical_specialtySettore MED/09 - Medicina Internamedia_common.quotation_subjectBlood PressureStroke subtype preventionInternal medicinemedicineAnimalsHumanscardiovascular diseasesStrokeAntihypertensive AgentsRandomized Controlled Trials as Topicmedia_commonPharmacologyAspirinbusiness.industryDipyridamoleAtherosclerosismedicine.diseaseSurgeryStrokeDipyridamoleClinical trialBlood pressureCardiologyCardiology and Cardiovascular MedicineComplicationbusinessLipohyalinosisPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct